VIM and small cell lung carcinoma: Although VIM is well known as an effector molecule rather than a dominant transcriptional regulator, such a finding is still of significant clinical implications, as it offers more convenient and accurate IHC‐based criteria for pathologists to classify most SCLC tumors into one of the four subtypes, and consequently guides targeting and personalized therapy strategies.